Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 53.7%

Neg 53.7% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.